Last reviewed: August 30, 2026. Educational content for adults 21+. This is not medical or legal advice. Kiody does not sell concentrated 7-OH products.
The short answer
A defensible kratom best-by or expiration date should be supported by evidence for the specific product, formula, package and labeled storage conditions. There is no single shelf-life period that can responsibly be assigned to every leaf powder, capsule, extract, liquid or gummy.
The strongest support normally comes from a written stability program that:
- starts with representative finished-product batches;
- stores them in the same commercial container-closure system customers receive;
- uses defined conditions and planned time points;
- tests attributes capable of changing over time;
- uses methods suitable for the product matrix and purpose;
- trends the actual numerical data, not only pass/fail boxes;
- investigates atypical or failing results; and
- assigns a date no longer than the evidence supports.
A printed date alone does not prove identity, safety, quality, legal status or proper storage after purchase. An initial certificate of analysis is a snapshot of the sampled lot around one point in time. Stability testing asks a different question: does the packaged product remain within its approved specifications through the proposed dating period?
First, an important regulatory distinction
FDA’s current kratom information states that kratom has not been lawfully marketed in the United States as a conventional food or dietary supplement. Nothing in this guide implies FDA approval of kratom, any specific shelf life or any Kiody product. FDA and Kratom.
This guide uses dietary-supplement current good manufacturing practice provisions as a product-quality framework. Under 21 CFR §111.70, supplement manufacturers establish specifications for identity, purity, strength, composition and relevant contamination limits. 21 CFR §111.75 addresses testing or examination used to determine whether specifications are met. 21 CFR §111.465 addresses holding conditions that protect product quality and retention of reserve samples.
Part 111 recognizes shelf-life dating when a company uses it—for example, through the reserve-sample retention rule—but the cited provisions do not prescribe one universal shelf life for kratom. A company that prints a date should be able to explain the evidence and decision process behind it.
FDA and ICH stability guidance for human drugs provides detailed technical concepts such as real-time studies, accelerated conditions, representative batches and testing in the proposed commercial package. Those documents apply to drug products, not automatically to kratom. This article cites them only as clearly labeled technical benchmarks, not as a claim that kratom is an approved drug or that every drug-specific condition is legally required for kratom. FDA Q1A(R2) Stability Testing of New Drug Substances and Products; FDA Expiration Dates—Questions and Answers.
Five terms that should not be treated as synonyms
Shelf life
Shelf life is the supported period during which an unopened product is expected to remain within its approved specifications when stored as labeled in its commercial package. It is a conclusion drawn from data and assumptions—not merely the elapsed time since packaging.
Best-by date
“Best by” commonly communicates the end of a manufacturer’s supported quality period. The precise meaning should be defined in the company’s procedure. It should not be used to suggest that a product is guaranteed safe before the date or automatically dangerous the day after it.
Expiration date
An expiration date often sounds more absolute to consumers. FDA explains in the drug context that an expiration date reflects the period during which a drug is known to remain stable under its labeled storage conditions, based on stability testing. That explanation is a useful technical principle, but it is drug-specific and does not establish a universal kratom requirement. FDA Expiration Dates—Questions and Answers.
Retest date
A retest date is not necessarily a consumer-facing expiration date. It can identify when stored raw material should be retested before further use. The decision may concern continued suitability for manufacturing rather than the marketed shelf life of a finished package.
Opened-package or in-use period
An unopened pouch and a pouch opened every day do not face the same moisture, oxygen, light, handling or contamination conditions. If a company makes an “use within X days after opening” statement, that period deserves its own rationale or study. Unopened-package data should not silently be converted into an in-use claim.
What a stability program is trying to learn
A stability program should begin with the question, “Which characteristics could change enough to affect product quality or the truthfulness of the label?” The answer depends on the form and formulation.
Potential attributes include:
- Botanical identity and physical character: appearance, color, odor, texture, caking or visible foreign material;
- Alkaloid composition: results for mitragynine, 7-OH and any other alkaloids included in an approved specification;
- Microbiological quality: specified pathogens and indicator or count tests chosen for the product;
- Moisture or water activity: measures that can help describe susceptibility to caking, physical change or microbial growth;
- Package performance: seal integrity, closure torque where relevant, leaks, punctures, broken induction seals, desiccant condition or other package-specific checks;
- Dosage-form performance: capsule integrity, liquid resuspension, gummy texture or tablet disintegration where applicable;
- Net quantity or delivery performance: evaporation, leakage, pump delivery or unit-weight changes where relevant; and
- Organoleptic and physical change: separation, sedimentation, crystallization, hardening, fading or odor change.
Not every release test must appear at every stability time point. Some contaminants are not expected to form during normal storage, while other attributes can shift. The choice should come from a written, product-specific risk assessment—not from copying a generic panel.
A passing stability panel also has limits. It does not prove that every package in a lot is identical, that the product was always stored correctly, that an untested contaminant is absent or that the product may legally be sold in every jurisdiction.
Release testing and stability testing answer different questions
Release testing asks whether the lot met approved specifications when the batch was evaluated for distribution. Stability testing asks whether selected attributes remain acceptable as time passes under defined conditions.
| Question | Release testing | Stability testing |
|---|---|---|
| Primary purpose | Decide whether a lot meets release specifications | Support the proposed dating period and storage statement |
| Timing | Near manufacture or release | At planned intervals over time |
| Package | May involve bulk or finished product depending on the program | Should represent the marketed container-closure system |
| Data view | One principal time point | Trend across multiple time points |
| Main risk | Releasing a nonconforming lot | Assigning a longer date than evidence supports |
A company cannot ordinarily support a 24-month shelf life merely because a lot passed one COA on day zero. Likewise, a stability lot that passes at 24 months does not erase a release failure or unexplained deviation.
Product form changes the stability question
Whole or powdered botanical leaf
For dry botanical material, the package’s resistance to moisture, light and physical damage can be important. Powder presents substantial surface area and may cake, change odor or take up moisture if the package or storage environment is poorly controlled. Relevant measures may include appearance, moisture or water activity, microbiology, alkaloid composition and seal integrity.
This does not mean that a single water-activity result determines shelf life. Water activity is one useful measurement within a larger quality assessment. A low initial result cannot prove that a compromised pouch will remain protective for two years.
Pure-leaf capsules
Kiody describes its leaf capsules as containing approximately 500 mg of pure leaf powder per capsule. Capsule studies may need to evaluate both the fill and the shell. Shell brittleness, softening, deformation, discoloration and closure problems can be relevant even when the powder’s alkaloid result remains within specification.
The bottle or pouch, desiccant, induction seal and headspace may differ from the packaging used for loose powder. Therefore, bulk-powder stability cannot automatically support the same date for finished capsules.
Extract powders
Extracts may contain higher alkaloid concentrations and may use carriers or processing aids. Hygroscopic behavior, carrier interactions, assay range, uniformity and packaging needs can differ from leaf. A ratio claim such as “10:1” is not itself a stability specification and does not establish how potency behaves over time.
Liquid products
Liquids introduce questions such as pH, preservation, solvent composition, evaporation, leakage, sedimentation, microbial susceptibility and resuspension. A clear layer or settled material is not automatically a failure, but the product should have an approved physical specification and a validated instruction if shaking is necessary.
Freeze-thaw or high-temperature shipping excursions may matter more for a liquid than for a sealed dry powder. The study should reflect credible distribution and use conditions without pretending that every possible abuse can be simulated.
Gummies or other water-containing formats
Gummies add water activity, texture, ingredient interactions, unit uniformity, packaging migration and microbial considerations. Stability evidence for leaf powder does not support a gummy simply because both products contain the same botanical ingredient.
Enhanced or concentrated 7-OH products
Concentrated, enhanced, synthesized or semi-synthesized products require separate analytical and legal scrutiny. A stability study cannot transform a prohibited or unapproved product into a lawful one. Kiody does not sell concentrated 7-OH.
The package is part of the product’s stability system
Stability evidence should normally use the package in which the product will be marketed. FDA’s drug-specific Q1A(R2) guidance describes studying dosage forms in the proposed container-closure system. FDA’s container-closure guidance likewise treats the package as part of protecting a product through shelf life. These are technical benchmarks here, not kratom-specific mandates. FDA Q1A(R2); FDA Container Closure Systems Guidance.
For a kratom product, packaging questions may include:
- What are the pouch film layers or bottle resin?
- Is the closure child-resistant, tamper-evident or neither?
- Is there an induction seal, liner or zipper?
- Is a desiccant present, and is it suitable for the package volume and intended period?
- Does the product contact an inner bag before the retail container?
- What is the fill volume and headspace?
- Does the package protect against relevant light exposure?
- Has the seal process been qualified and monitored?
- Are the stability samples packaged on representative production equipment?
- Does the study cover the smallest or largest package, or is bracketing scientifically justified?
Changing from an opaque multilayer pouch to a clear jar is not merely a graphic redesign. Removing a desiccant, changing a liner, reducing film thickness or changing fill size can alter the product’s exposure to the environment. A change-control procedure should assess whether existing stability evidence still applies.
Package claims also require restraint. “UV resistant,” “airtight,” “oxygen barrier” and “moisture proof” are not interchangeable. The supplier’s material specification, finished-package integrity, sealing process and real product data all matter.
Real-time, accelerated and stress studies
Real-time studies
Real-time—or long-term—stability stores the packaged product under the intended labeled conditions and evaluates it at planned intervals. This is the most direct support for how the product performs through the proposed period.
For a 24-month claim, the strongest evidence ordinarily includes real-time observations extending to that period. A company may use a scientifically governed initial dating strategy while real-time data accumulates, but the rationale, limits and update plan should be documented.
Accelerated studies
Accelerated studies use conditions intended to increase the rate of relevant change. They can reveal vulnerabilities, compare packages or support an initial hypothesis. They should not be converted into shelf life through an unexplained multiplier.
For example, “eight weeks at high temperature equals two years at room temperature” is not a universal law. Different changes may follow different mechanisms. Excessive heat may create a failure mode that does not occur at labeled conditions, while a light-sensitive or moisture-driven change may be missed if the accelerated design does not challenge it appropriately.
An accelerated study is most useful when it has:
- defined conditions and tolerances;
- a scientifically justified relationship to anticipated degradation or physical change;
- suitable controls;
- stability-indicating methods;
- predefined acceptance and trend rules; and
- ongoing confirmation with real-time data.
Stress or forced-change studies
Stress studies deliberately challenge a sample with heat, humidity, light, oxidation, pH or other conditions to understand potential changes and demonstrate that a method can distinguish the analyte from relevant change products. They are not consumer shelf-life simulations.
A stressed sample that changes dramatically may help prove that an assay is stability-indicating. It does not mean the marketed product will experience the same change under normal storage.
Shipping-excursion studies
Distribution can expose packages to hot vehicles, cold conditions, vibration, pressure and repeated handling. A distribution study can evaluate credible excursions and package resilience. It should not be used to excuse indefinite storage outside labeled conditions.
The resulting procedure should define what happens when a warehouse temperature alarm, delayed shipment or frozen liquid is reported: accept based on evidence, inspect and test, quarantine for investigation or reject.
Choosing representative batches
A single hand-packed pilot sample may not represent routine production. Stability batches should be representative of the product, formula, process, package and normal variability they are intended to support.
Selection factors include:
- botanical or extract supplier;
- input-lot age and composition;
- manufacturing site and equipment;
- batch size;
- blending, milling or encapsulation process;
- package supplier and lot;
- fill size and headspace;
- seal settings;
- season or environmental conditions; and
- initial results near the center or edge of an approved range.
FDA’s Q1A(R2) drug guidance uses multiple primary batches and discusses bracketing and matrixing. The practical lesson for a kratom quality program is not to copy a drug protocol blindly; it is to avoid basing a broad shelf-life claim on one unusually favorable package or lot.
Where several package sizes use the same materials and closure design, a company may consider a documented bracketing rationale. The worst case is not always obvious. A small package may have more headspace relative to product mass, while a large flexible pouch may face different seal or compression risks.
Time points should reveal a trend
Stability testing needs enough observations to show what is happening over time. A beginning and end result can miss an intermediate excursion or obscure the shape of a trend.
An illustrative 24-month real-time plan might include initial, 3-, 6-, 9-, 12-, 18- and 24-month testing. That schedule is an example, not a universal legal requirement. Higher-risk liquids or early development work may warrant more frequent observations; a well-characterized dry product may support another scientifically justified plan.
Each scheduled pull should identify:
- batch and package configuration;
- chamber or storage-location identifier;
- intended and actual pull date;
- allowable pull window;
- condition history and excursions;
- sample quantity removed;
- tests to perform;
- methods and versions;
- results and qualifiers;
- deviations or investigations; and
- quality-unit review.
Testing every sample at the end of the study defeats the purpose if the sample was removed earlier and then stored under uncontrolled conditions. Pull, storage and testing timelines need control.
“Room temperature” is too vague for a protocol
Consumer instructions may say “store in a cool, dry place,” but the study protocol needs measurable conditions. The company should define the intended storage range, monitoring system, alert or action rules and response to excursions.
Important variables can include:
- temperature;
- relative humidity;
- light exposure;
- orientation for liquids;
- freeze-thaw cycles;
- package opening frequency for in-use work; and
- whether samples remain in cartons or secondary packaging.
A logged chamber set point is not the whole record. The program should maintain calibration and monitoring evidence, alarm history, excursion assessments and mapping or qualification appropriate to the storage system.
For customer-facing language, avoid implying that refrigeration, freezing or transferring powder into another container will always extend shelf life. Those actions can create condensation, package damage or identification problems. Storage advice should match the product’s supported label and packaging.
Stability-indicating methods matter
A method can be precise on day zero without being capable of detecting meaningful change over time. A stability-indicating method can measure the target attribute accurately in the presence of relevant changes, interferences or degradation products expected in the study.
For an alkaloid method, reviewers should ask:
- Does it separate mitragynine, 7-OH and other reportable compounds from relevant interferences?
- Is the method suitable for leaf powder, capsules, extract, liquid or gummy matrix?
- Are calibration standards and reference materials appropriate and traceable?
- Are extraction recovery and matrix effects evaluated?
- Can the method detect change near the approved limit?
- Are unknown or new peaks reviewed rather than ignored?
- Are integration and reprocessing rules controlled?
- Does the report state whether results are as-received or dry-weight based?
Stress work may help demonstrate selectivity, but the company should not identify an unknown chromatographic peak as a specific compound without suitable analytical evidence.
Microbiology methods also need matrix suitability. A preservative, high sugar content or extract matrix can inhibit recovery and create a falsely reassuring result if method suitability is not established. Moisture content and water activity are related but different measurements and should not be used interchangeably.
Laboratory controls and records are addressed in 21 CFR Part 111, Subpart J. FDA’s current dietary-supplement inspection program also directs investigators to examine specifications, testing, laboratory controls, records and reserve samples. FDA Compliance Program 7321.008—Dietary Supplements.
Alkaloid results, 7-OH and shelf-life decisions
Alkaloid data may be important to composition specifications and legal review. Three different reporting bases should not be confused:
- percentage of total product dry weight;
- milligrams per unit or package; and
- percentage of total alkaloid composition.
A stability report should preserve the same units, basis and calculation rules used in the specification. If moisture changes, a dry-weight result may move differently from an as-received result. The report should not switch denominators between time points without showing the conversion.
If a legal or internal limit is involved, the shelf-life decision should consider whether the product remains within that limit throughout the supported period—not merely at release. Results close to a boundary deserve predefined handling for rounding, measurement uncertainty, retesting and trend escalation.
Do not assume a detected increase or decrease identifies a chemical mechanism. The observation may reflect actual product change, moisture movement, sampling variation, extraction recovery, reference-standard issues, integration decisions or calculation error. An investigation should evaluate the evidence before reaching a conclusion.
Current federal 7-OH and derivative status as of August 30, 2026
This legal note is time-sensitive and should be rechecked immediately before publication.
DEA’s July 6, 2026 notice proposes temporarily placing 7-OH above a specified threshold in Schedule I. The proposal describes a threshold of 0.050% by dry weight and an alternative article trigger involving one milligram or more of 7-OH per unit. It is not the same as a final effective scheduling order. On August 26, DEA extended the comment period through September 10, 2026. Federal 7-OH proposed rule; comment-period extension.
Separately, DEA’s temporary order placing mitragynine pseudoindoxyl, MGM-15 and MGM-16 in Schedule I became effective August 26, 2026. That order is effective; it should not be described as merely proposed. Effective DEA derivative order.
Stability does not create a legal safe harbor. A product does not become lawful because it tested below an internal limit at release, remained physically unchanged or carried an earlier manufacturing date. State and local rules may use other thresholds, denominators, product definitions or outright prohibitions. Ordinary botanical leaf must therefore remain clearly distinguished from enhanced, concentrated, synthesized or semi-synthesized products in both quality and legal review.
Trending is more informative than a row of green boxes
A stability summary should preserve numerical results whenever the method produces them. “Pass, pass, pass” hides movement toward a limit.
Consider an illustrative moisture specification of not more than 8.0%:
| Time | Result | Reported decision |
|---|---|---|
| Initial | 5.2% | Pass |
| 3 months | 5.4% | Pass |
| 6 months | 6.3% | Pass |
| 9 months | 7.6% | Pass |
| 12 months | 8.3% | Fail |
The 9-month point passes, but the upward trend was already meaningful. A trend rule could require review before a result reaches the formal limit. That allows investigation of package integrity, chamber conditions, method variation or other causes before the next pull fails.
Useful trend tools can include:
- absolute and percentage change from initial;
- rate of change over defined intervals;
- batch-to-batch comparison;
- package-configuration comparison;
- control charts or alert bands;
- regression where scientifically appropriate; and
- review of uncertainty near a decision boundary.
A mathematical line should not replace scientific judgment. Extrapolation beyond observed data requires a suitable model, adequate data and documented assumptions. A straight line fitted to three noisy values does not automatically justify an extra year of shelf life.
Five worked stability reviews
The following examples are educational. The specifications and values are hypothetical and do not establish Kiody requirements or legal limits.
Scenario 1: Powder in a resealable pouch
A leaf powder is packaged in a multilayer pouch with a zipper and heat seal. The proposed best-by period is 12 months. Initial, 3-, 6-, 9- and 12-month samples are tested for appearance, water activity, moisture, microbiology and specified alkaloids.
At nine months, moisture is still within specification but trending upward. At 12 months it exceeds the approved limit, and several pouches show weak top seals.
Review: The data do not support a 12-month period for that package as produced. Quality should investigate the seal process, package lot, storage history and method. A shorter supported period, improved packaging or a new study may be needed. Discarding the 12-month result because the nine-month point passed would be scientifically weak.
Scenario 2: The same powder moves into capsules
The company has 18 months of acceptable powder-in-pouch data. It introduces pure-leaf capsules in a high-density polyethylene bottle with a desiccant and prints the same 18-month date.
Review: The powder data are relevant background but do not automatically establish capsule-in-bottle shelf life. The capsule shell, bottle, liner, desiccant, headspace and filling process create a different configuration. The company needs a documented bridging rationale plus representative capsule stability data.
Scenario 3: A liquid settles during storage
A liquid product develops sediment at six months. It returns to uniform appearance after the labeled shaking procedure. Alkaloid results remain within the approved range, but unit-to-unit delivered amount has not been evaluated.
Review: “Shake well” does not close the investigation by itself. The program should define acceptable sedimentation and resuspension, verify that normal shaking restores uniform delivery, examine microbial and preservative controls where relevant, and confirm package performance. Physical change can matter even when an assay passes.
Scenario 4: Eight accelerated weeks are multiplied into two years
A pouch remains within specification for eight weeks at an elevated temperature. The marketing team proposes a 24-month date using a simple twelve-times multiplier.
Review: The conversion is unsupported unless the company has a scientifically justified model and confirms it with real-time data. The accelerated study may be useful package-screening evidence, but it is not automatically equivalent to 24 months at the labeled condition.
Scenario 5: A 7-OH result approaches a decision boundary
A botanical product starts below an applicable internal or legal review threshold. Later time points move closer to the boundary. The values also carry method uncertainty, and the product’s moisture changes over time.
Review: Quality should verify the reporting basis, moisture correction, sample preparation, method performance, uncertainty, calculations and trend. It should apply the predetermined decision rule and current jurisdiction-specific law. Averaging the late result with an earlier low result would not show that every point remained compliant. A passing physical inspection does not resolve the alkaloid question.
What to do with an out-of-specification or atypical result
An unexpected result should trigger a documented assessment, not an automatic retest until something passes. 21 CFR §111.113 requires quality-control review and approval of investigations into deviations or unanticipated occurrences in the dietary-supplement framework.
A stability investigation can include:
- Verify sample identity, storage condition and pull history.
- Review chamber alarms, excursions and monitoring records.
- Review sample preparation, standards, calculations, audit trails and instrument performance.
- Examine the package and compare retained units.
- Compare other time points, batches and package configurations.
- Determine whether a confirmed laboratory error exists.
- If justified, perform predefined retesting or resampling without testing into compliance.
- Assess distributed lots, current dating and any need for market action.
- Document root cause or most supportable conclusion.
- Implement corrective and preventive actions and evaluate effectiveness.
FDA’s out-of-specification guidance applies to drug production, so it is not presented here as a kratom-specific legal requirement. It can still be a useful technical reference for laboratory-investigation principles when clearly labeled that way. FDA Investigating Out-of-Specification Test Results Guidance.
Extending a shelf life requires controlled evidence
If a 12-month product continues to meet specifications at 18 and 24 months, the company may consider extending the date. A controlled process should address:
- which batches and configurations support the extension;
- whether all scheduled results are complete and approved;
- whether any trends or investigations weaken the conclusion;
- whether methods or specifications changed during the study;
- whether the commercial package is unchanged;
- whether complaints or field data reveal a problem;
- whether existing inventory can be relabeled and under what authority; and
- how the revised date will be documented in master manufacturing, label and distribution records.
The same discipline applies when shortening a date. Quality should identify affected inventory, labels, websites and customer communications. Changing a date in a product database without the underlying quality decision is not a complete stability program.
Reserve samples and continuing verification
Under the dietary-supplement framework, 21 CFR §111.465 requires reserve samples to be held using the same container-closure system in which the packaged product is distributed, or one with essentially the same protective characteristics. If shelf-life dating is used, reserve samples are generally retained for one year past that date; if it is not used, the rule uses two years from the date of distribution of the last batch associated with the reserve sample.
Reserve samples are not automatically stability samples. A reserve may be stored for complaint investigation or later examination without being part of a predefined stability protocol. Conversely, a stability chamber sample may have planned pulls that consume units. The records should distinguish the two programs while maintaining enough units for their purposes.
Continuing or annual stability work can help determine whether routine production still behaves like the original supporting batches. It can detect supplier, process, package or seasonal changes that were not obvious at release.
Complaints and field information belong in the stability review
Laboratory data are only one source of evidence. Complaints about caking, broken capsules, leaking bottles, unusual odor, mold, swollen packages or ineffective seals can expose a stability or packaging issue.
Complaint trends should be connected to:
- product and lot;
- manufacturing and packaging dates;
- package supplier and lot;
- distribution region or route;
- customer-reported storage;
- time since opening;
- photographs or returned samples;
- laboratory and retain-sample examination; and
- similar events across lots.
A complaint does not prove the product caused an effect or that an entire lot failed. It does require a proportionate, documented evaluation. Conversely, the absence of complaints is not proof of a 36-month shelf life.
Twenty shelf-life and stability warning signs
Pause and request more information when any of these appears:
- Every kratom form receives the same shelf life without product-specific support.
- A day-zero COA is presented as proof of a multi-year date.
- The company cannot identify the batches used in the stability study.
- Samples were stored in laboratory jars rather than the commercial package.
- “Room temperature” is the only condition recorded.
- Accelerated weeks are converted into years with an unexplained multiplier.
- The protocol has no predefined tests, time points or acceptance criteria.
- Only pass/fail labels remain; numerical results were discarded.
- A failing time point is averaged with passing time points.
- Repeated retesting continues until a passing result appears.
- The package or desiccant changed without stability impact assessment.
- Bulk powder data are used for capsules, gummies and liquids without a bridge.
- The assay method has not been shown to detect relevant change.
- Moisture, water activity and relative humidity are treated as the same measure.
- ND is reported without a numerical reporting limit.
- Dry-weight and as-received alkaloid results are compared without conversion.
- Unknown chromatographic peaks are ignored or casually named.
- A date is extended while an investigation remains open.
- The date is described as proof that a product is legal in every jurisdiction.
- “Natural,” “traditional” or “lab tested” replaces the actual study evidence.
No single warning sign proves misconduct. It identifies a gap that deserves an answer.
A proposed 36-field Kiody stability review record
Kiody could use the following internal review fields when evaluating supplier or manufacturer stability evidence. This is a proposed record, not a statement that every field is legally required in every situation.
Product and dating
- Product name
- SKU or internal identifier
- Product form
- Formula or composition version
- Proposed shelf life
- Date terminology used: best-by, expiration, retest or in-use
- Labeled storage statement
- Intended market jurisdictions
Batches and packaging
- Stability batch numbers
- Manufacture and packaging dates
- Batch sizes and representativeness rationale
- Ingredient or botanical supplier lots
- Commercial container-closure description
- Package component suppliers and lots
- Fill size and headspace
- Seal, liner, zipper, desiccant or induction-seal details
- Packaging-line and seal-process qualification reference
- Bracketing or matrixing rationale, if used
Protocol and storage
- Approved protocol and version
- Real-time conditions and tolerances
- Accelerated or stress conditions and purpose
- Shipping-excursion or freeze-thaw design, if relevant
- Chamber or storage-location identifier
- Planned time points and pull windows
- Actual pull and test dates
- Alarm, excursion and deviation records
Testing and decisions
- Attributes tested at each time point
- Approved specifications and sources
- Methods, versions and laboratory identity
- Matrix suitability and stability-indicating evidence
- Results, units, basis and qualifiers
- Trend or statistical review
- OOS, atypical or complaint investigations
- Package-change and process-change assessments
- Quality-unit conclusion and approved dating period
- Ongoing stability commitment and next review date
The record should link to the actual data, not merely summarize that “stability passed.”
Practical consumer storage literacy
Consumers cannot recreate a manufacturer stability chamber, but they can avoid undermining the package’s intended protection.
General label-following habits include:
- Keep the product in its original, labeled container unless the label directs otherwise.
- Close the package fully after each use.
- Keep wet utensils and hands out of dry powder.
- Protect the package from excessive heat, moisture and direct light as the label instructs.
- Do not use a product from a torn, leaking, unsealed or badly damaged package.
- Preserve the lot number and best-by information.
- Do not combine remnants of different lots into one container.
- Do not rely on smell or appearance alone to establish quality.
- Contact the seller with the product name, lot, date and photographs if a package appears abnormal.
- Follow current law in the destination jurisdiction.
These steps do not guarantee safety or extend the printed period. They preserve traceability and reduce avoidable handling problems.
Frequently asked questions
How long does kratom last?
There is no defensible universal answer for all kratom products. The supported period depends on the specific formula, form, package, storage conditions, specifications, methods and stability data.
Does kratom expire?
A manufacturer may assign a best-by or expiration date based on its quality program. The meaning should be defined and supported. A printed date does not itself prove that every quality attribute was studied or that the product is automatically safe before the date.
Is a best-by date the same as an expiration date?
Not necessarily. Companies should define the terms in their procedures and use consumer-facing language consistently. “Best by” often emphasizes the supported quality period, while “expiration” may sound more absolute.
Can a COA prove a two-year shelf life?
A single release COA cannot. A stability program needs data over time for representative product in representative commercial packaging.
Is accelerated testing enough?
It can provide useful supporting information, but an unexplained time multiplier is not adequate. Accelerated conclusions should be scientifically justified and confirmed with real-time data.
What does real-time stability mean?
It means storing the product under defined conditions representative of the labeled storage and testing planned attributes at intervals over the proposed period.
Must stability samples use the retail package?
Using the commercial container-closure system gives the most directly relevant evidence. Data from another package require a scientifically justified bridge showing comparable protection.
Can powder stability support capsule dating?
Not automatically. The shell, fill process, bottle or pouch, desiccant and headspace create a new finished-product configuration.
Does refrigeration always make kratom last longer?
No universal claim is supportable. Refrigeration can introduce condensation or other problems when a package is opened. Follow the product’s evidence-based labeled storage instructions.
Should kratom be frozen?
Do not assume freezing extends quality. Freeze-thaw can affect some liquids, packages and ingredients. Use only storage conditions the product’s program supports.
What are the most useful stability tests for leaf powder?
The selection is product-specific. Appearance, package integrity, moisture or water activity, microbiology and relevant alkaloid composition are common candidates, but a written risk assessment should determine the panel.
Are moisture content and water activity the same?
No. Moisture content measures the amount of water under the stated method. Water activity describes available water in a different way. They can be related but are not interchangeable.
Does “not detected” mean an analyte is absent throughout shelf life?
No. It means the analyte was not reported above the method’s stated detection or reporting capability in the tested sample at that time. The limit and method matter.
Can a company average stability results to obtain a pass?
Averaging time points can conceal a failure and does not prove the product met its specification at every interval. Any statistical treatment must match a predefined, scientifically valid decision rule.
What happens when one time point fails?
The sample, laboratory work, storage condition, package, other batches and distributed product implications should be investigated. Retesting should follow a controlled plan rather than continue until a pass appears.
Can shelf life be extended later?
Potentially, if approved real-time data, trends, investigations, packages and methods support the extension. The change should pass through quality and label controls.
Does a stability pass prove the product is legal?
No. Quality and legality are separate questions. Federal, state and local restrictions may distinguish botanical leaf from extracts, enhanced 7-OH and controlled derivatives.
Are mitragynine pseudoindoxyl, MGM-15 and MGM-16 treated like ordinary leaf?
No. DEA’s temporary Schedule I order for those three substances took effect August 26, 2026. Ordinary botanical leaf should not be collapsed into the same product category, and product-specific legal review remains necessary.
Sources and further reading
Primary government and consensus sources used for this draft:
- FDA and Kratom — FDA’s current federal regulatory position.
- 21 CFR Part 111 — dietary-supplement current good manufacturing practice framework.
- 21 CFR §111.70 — specifications.
- 21 CFR §111.75 — testing and examination.
- 21 CFR §111.113 — quality-control review of investigations.
- 21 CFR §111.465 — holding and reserve samples.
- 21 CFR Part 111, Subpart J — laboratory operations.
- FDA Compliance Program 7321.008—Dietary Supplements — current inspection framework.
- FDA Expiration Dates—Questions and Answers — drug-specific technical explanation of expiration dating.
- FDA Q1A(R2) Stability Testing of New Drug Substances and Products — drug-specific technical stability framework.
- FDA Container Closure Systems Guidance — drug and biologic packaging guidance used only as a technical benchmark.
- FDA Investigating Out-of-Specification Test Results — drug-specific laboratory-investigation guidance used only as a technical benchmark.
- DEA proposed temporary scheduling of 7-OH above a specified threshold, July 6, 2026.
- DEA extension of the 7-OH comment period through September 10, 2026.
- Effective temporary Schedule I order for mitragynine pseudoindoxyl, MGM-15 and MGM-16, August 26, 2026.